Request Trial
shutterstock_405846475_nils_versemann
Nils Versemann / Shutterstock.com
24 March 2022PharmaMuireann Bolger

Sun unit resolves antitrust lawsuit for $485m

Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Influential Women in IP 2026: Who made the list?
7 July 2026   Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.
Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026   Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.


Editor's picks

What’s at stake in Australia’s biggest pharma patent appeal in years?
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

Editor's picks

Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Biotech
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen
Exelixis opens two-front patent dispute over Cabometyx copies
UPC upholds injunction in Invisalign maker’s software dispute with rival
BioNTech and Pfizer secure big European win over mRNA patent
Pillsbury nabs ‘veteran’ IP litigator and trial lawyer from Goodwin
Influential Women in IP 2026: Who made the list?
WilmerHale trade secrets expert moves to new firm
UPC revives patent, but timing sinks Guardant’s appeal